Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

verubecestat

Known as: N-(3-(3-amino-5,6-dihydro-2,5-dimethyl-1,1-dioxido-2H-1,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
BACKGROUND Prodromal Alzheimer's disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid… Expand
  • figure 1
  • table 1
  • table 1
  • figure 2
Is this relevant?
2019
2019
In the present study, an ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) approach was designed to… Expand
Is this relevant?
Highly Cited
2018
Highly Cited
2018
BACKGROUND Alzheimer's disease is characterized by the deposition of amyloid‐beta (Aβ) plaques in the brain. Aβ is produced from… Expand
  • table 1
  • table 1
  • figure 1
  • figure 2
Is this relevant?
2018
2018
Verubecestat is an inhibitor of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) being evaluated in clinical trials for… Expand
Is this relevant?
2018
2018
The development of a commercial manufacturing route to verubecestat (MK-8931) is described, highlights of which include the… Expand
Is this relevant?
2018
2018
Cleavage of amyloid precursor protein by beta-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) leads to amyloid-beta (A… Expand
Is this relevant?
2017
2017
Verubecestat is a potent BACE1 enzyme inhibitor currently being investigated in Phase III trials for the treatment of mild-to… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2016
Highly Cited
2016
β-Amyloid (Aβ) peptides are thought to be critically involved in the etiology of Alzheimer’s disease (AD). The aspartyl protease… Expand
Is this relevant?
2016
2016
Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity… Expand
Is this relevant?
2016
2016
Verubecestat is an inhibitor of β-secretase being evaluated for the treatment of Alzheimer's disease. The first-generation route… Expand
Is this relevant?